AC Immune reports positive interim data from ABATE trial of ACI-24
- AC Immune (NASDAQ:ACIU) reported 12-month interim data from the Phase 1b/2 ABATE trial of ACI-24 in patients with prodromal Alzheimer’s disease.
- ACI-24 was generally safe and well tolerated, with no ARIA-E, and showed anti-Aβ antibody responses at all dose levels.
- A new AD4 cohort is testing an added adjuvant to enhance immunogenicity.
AC Immune (NASDAQ:ACIU) reported 12-month interim data from the Phase 1b/2 ABATE trial of ACI-24 in 74 patients with prodromal Alzheimer’s disease across cohorts AD1-AD3.
According to the company, ACI-24 has been generally safe and well tolerated, with no ARIA-E observed.
The vaccine candidate showed anti-Aβ antibody responses at all dose levels, with evidence of a dose response.
A new AD4 cohort is testing an added adjuvant to enhance immunogenicity.
The data support continued development of ACI-24 as a potential active immunotherapy for early Alzheimer’s disease.
AC Immune is focused on developing precision therapies and diagnostics for neurodegenerative diseases, with ACI-24 as a key program in its Alzheimer’s pipeline.
The company continues to advance its vaccine-based approach to addressing amyloid pathology in Alzheimer’s disease.
More from United States
Arm Q2 revenue hits $1.44B as AI chip demand surges
Qualcomm Q4 earnings beat estimates as auto sales jump 89%
Melco Resorts Q3 revenue falls 10% to $1.17 billion
Emerson Q4 revenue accelerates 7% to $5.2 billion
Flowco Q3 revenue revs up 46% to $258.6 million
Clear secure Q3 revenue hits $292.9M as top line expands 27.8%
